Authors
Safonova O.O.1, Maximkin D.A.1, Loginova S.K.1, Kim I.E.2, Shugushev Z.Kh.1
1 Peoples’ Friendship University of Russia named after Patrice Lumumba, Moscow
2 Private Central Clinical Hospital. Russian Railways-Medicine, Moscow
Abstract
Purpose. To evaluate the long-term (24 months) results of drug-coated balloon catheters in the treatment of bifurcation stenoses of the left main coronary artery (LMCA).
Methods. A controlled, randomized, prospective study included 150 patients who underwent provisional T-stenting left main coronary artery were included in the study. Patients were randomised into 2 groups by envelope method. In group 1 (n = 75) – final kissing-dilatation after provisional LMCA T-stenting was performed with a drug-coated balloon (DCB) – in the lateral bifurcation branch and with a standard uncoated balloon catheter – in the main branch. In group 2 (n = 75) – final kissing-dilatation was performed with a non-plaque balloon catheter in both the main and lateral bifurcation branches. Patients of both groups were additionally randomised into subgroups of ‘true’ and ‘false’ bifurcation stenoses (Medina classification). Inclusion criteria: bifurcation lesions of the left main coronary artery according to intravascular imaging methods (OST, IVUS); side branch diameter of at least 2.5 mm; confirmed myocardial ischemia in the bifurcation lesion basin (according to FFR, exercise tests, scintigraphy); stable angina of functional class II-IV or proven painless ischemia. Exclusion criteria: implantation of two stents for bifurcation lesion of the LMCA (culotte/crush); severe calcification of the LMCA; extended lesion (more than 25 mm); acute coronary syndrome; previous interventions on the LMCA; side branch diameter less than 2.5 mm; patient’s refusal of intervention. The long-term results were evaluated after 24 months.
Results. The long-term results were followed up in 133 patients. After 24 months, the rate of restenosis at the side branch orifice was significantly higher in Group 2 compared to Group 1, amounting to 19.2% and 8%, respectively (p = 0.044) (method used: Pearson Chi-square). However, when analyzing the cumulative MACE value after 24 months, no statistically significant differences were found (p = 0.303) (method used: Pearson Chi-square).
Conclusions. The use of drug-coated balloon catheters in patients with bifurcation stenosis of the left main coronary artery is an effective and safe method of treatment, and in some cases, it is the most effective and safe method of treatment.
Keywords: drug coated balloon, bifurcation stenosis, bifurcation stenting; left main coronary artery.
References
1. Louvard Y, Medina A. Definitions and classifications of bifurcation lesions and treatment. EuroIntervention. 2015; 11(SV): V23-V26. doi: 10.4244/ EIJV11SVA5.
2. Jens FL, Niels RH, Adrian B, et al. Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention. 2016; 12: 38-46. doi: 10.4244/ EIJV12I1A7.
3. Dash D. Recent perspective on coronary artery bifurcation interventions. Heart Asia. 2014; 6: 18-25. doi: 10.1136/heartasia-2013-010451.
4. Daniele G, Fernando A, Bo X, et al. The Romanian Academy; Romania: 2011. Drug-eluting balloons versus drug-eluting stents for the treatment of coronary in-stent restenosis; pp. 579-588. doi: 10.1016/j.jacc.2020.04.006.
5. Daniele G, Fernando A, Bo X, et al. Percutaneous coronary interventions for the treatment of stenoses in small coronary arteries: a network meta-analysis. JACC Cardiovasc Interv. 2016; 9(13): 1324-1334. doi: 10.1016/ j.jcin.2016.03.025.
6. Dario P, Michael D, Damiano R, et al. Drug-coated balloon combined with drug-eluting stent for the treatment of coronary bifurcation lesions: insights from the HYPER study. European Heart Journal Supplements. 2023; 25(SC): C79-C83. doi: 10.1093/eurheartjsupp/suad011.
7. Pier PL, Antonio C. Drug-Coated Balloons. Cardiac interventions today. 2024; 18(3).
8. José V, Fernando T-M, Marta H-B, et al. Long-term effectiveness of drug-coated balloon in the side branch treatment of bifurcation lesions. REC Interv Cardiol. 2023; 5: 7-13. doi: 10.24875/RECICE.M22000321.
9. Quan-Min J, Xin Z, Ya-Ling H, et al. A drug-eluting Balloon for the trEatment of coronarY bifurcation lesions in the side branch:a prospective multicenter ranDomized (BEYOND) clinical trial in China. Chin Med J. 2020; 133: 899-908.
10. Ziad A, Celina M. Yongl. Drug-Coated Balloons to Keep Interventions of the Side Branch Simple (KISS). Journal of the American College of Cardiology. 2025; 85(1): 16-18. doi: 10.1016/j.jacc.2024.09.020.
11. Daimy M, Dillen M, Pieter JV, et al. Bifurcation PCI with a hybrid strategy with drug- eluting balloons versus a stepwise provisional two- stent strategy: Rationale and design of the hybrid DEB study. Am Heart J. 2023; 266: 168-175. doi: 10.1016/j.ahj.2023.09.010.
12. Vassilev D, Mileva N, et al. Determinants of functional significance of coronary bifurcation lesions and clinical outcomes after physiology-guided treatment. Int J Cardiol Heart Vasc, 2021; 38: 100929. doi: 10.1016/ j.ijcha.2021.100929.
